ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2025
Comparison of the 2022 ACR/EULAR classification criteria with the 1990 ACR classification criteria for Takayasu arteritis.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimTakayasu arteritis (TAK) mostly affects the aorta and its major branches and has an unclear origin. This study aimed to compare the 1990 American College of Rheumatology (ACR) classification criteria with the 2022 ACR/European League Against Rheumatism (EULAR) classification criteria for TAK on the basis of clinical data analysis of patients with TAK and other major vascular diseases.
methodsThis retrospective study was conducted in a single-center. The results included 34 TAK patients routinely followed at a tertiary rheumatology center from October 2017 to February 2024. The accuracy, sensitivity, specificity, positive predictive values (PPV), negative predictive values (NPV), and area under the receiver operating characteristic (ROC) curve (AUC) of the classification criteria were compared.
resultsThe sensitivity (91.2%), specificity (90.9%), PPV (93.9%), NPV (86.9%), accuracy (94.4%) and AUC (0.983 (0.957-0.998)) of the 2022 ACR/EULAR classification criteria for TAK were higher than those of the 1990 ACR classification criteria for TAK (76.4%, 86.3%, 88.9%, 64.2% and 0.75, respectively), and the difference in AUC was statistically significant (0.860 (0.757-0.963), p < 0.001).
conclusionsThis study found that the 2022 ACR/EULAR classification criteria were more suitable for our patient population and had better classification performance than those in 1990, which can be supported in clinical practice. Our study needs to be supported by future multicenter prospective studies with larger patient numbers.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.